Additional data presentations explore potential utility of targeting NOP receptors in the treatment of insomnia disorders
STAMFORD, CT, USA I August 28, 2020 I Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and subsidiary of Purdue Pharma L.P., today announced results from two Phase 1b studies evaluating the safety, tolerability and efficacy of IMB-115 in patients with insomnia disorder. IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor impairment. The data were shared in an oral presentation (Oral Session O-01) on August 28 and a poster (Abstract ID #502) at the 34th Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2020).
IMB-115 is an internally discovered oral compound with a novel mechanism of action in clinical development for the treatment of sleep disorders, including insomnia. It is designed to bind to and activate the NOP receptor, a protein widely distributed in the central nervous system1 and involved in a wide range of biological functions.2
“Sleep disorders, particularly insomnia, impact millions of people in the U.S. About 10 percent of adults with insomnia experience side effects from treatments that are severe enough to cause daytime consequences;3 these patients often struggle to find relief despite available medications. This reinforces the need to explore new mechanisms in the brain that may contribute to challenges with sleep,” said Paul Medeiros, president, Imbrium Therapeutics. “These data add to the growing body of knowledge around IMB-115 and the NOP receptor pathway and underscore our commitment to advancing medical science to benefit patients.”
IMB-115 was evaluated by nighttime dosing in two separate Phase 1b randomized, double-blind, crossover, placebo-controlled sleep studies using polysomnography (PSG) that evaluated 52 patients with insomnia disorder. In Study #1, 22 patients received either 10 mg of IMB-115 or placebo orally for two consecutive nights. In Study #2, 30 patients received either 0.5, 1, 3 or 6 mg of IMB-115 or placebo orally for two consecutive nights. The primary endpoint for both studies was Sleep Efficiency (SE; or the ratio of the total sleep time divided by the time in bed [8 hours]). Secondary endpoints included Wakefulness After Sleep Onset (WASO; or waking up after falling asleep) and several additional PSG as well as patient diary measures of efficacy.*
Results from both studies demonstrated a dose-dependent, statistically significant and clinically meaningful enhancement in SE (1 mg – 10 mg) and reduction in WASO (0.5 mg – 10 mg), see table below. Additionally, with the exception of Latency to Persistent Sleep (LPS) and subjective Sleep Latency (sSL), the data showed that all other objective and subjective measures of sleep were statistically significantly improved at IMB-115 doses ≥3 mg as compared to placebo. While there was a numeric, dose-dependent trend for improvement in sleep latency with increasing doses of IMB-115, at doses of <3 mg and <10 mg IMB-115 did not achieve statistically significant improvement in sSL and LPS, respectively.
IMB-115
Dose |
N |
Sleep Efficiency (%) |
WASO (min) |
LS Mean
(95% CI) |
P Value |
LS Mean
(95% CI) |
P Value |
| 0.5 mg |
30 |
4.1 (1.7, 6.6) |
0.001 |
-24.3 (-34.5, -14.2) |
<0.001 |
| 1 mg |
30 |
6.7 (4.3, 9.2) |
<0.001 |
-31.8 (-41.9, -21.6) |
<0.001 |
| 3 mg |
29 |
9.7 (7.2, 12.1) |
<0.001 |
-46.4 (-56.6, -36.2) |
<0.001 |
| 6 mg |
30 |
11.0 (8.6, 13.5) |
<0.001 |
-50.8 (-60.9, -40.7) |
<0.001 |
| 10 mg |
19 |
11.8 (7.2, 16.4) |
<0.0001 |
-38.5 (-55.9, -21.0) |
0.0003 |
IMB-115 was well-tolerated across the doses, ranging from 0.5 to 10 mg in both studies. In Study #1, 14 subjects (63.6%) reported treatment-emergent adverse events (TEAEs) of mild severity and 2 subjects (9.1%) reported TEAEs of moderate severity. In Study #2, 21 subjects (70%) reported TEAEs of mild severity and 4 subjects (13%) reported TEAEs of moderate severity. There were no severe TEAEs in either study. There were no AEs leading to study drug withdrawal or discontinuation of treatment with IMB-115. Somnolence (or drowsiness) was the most frequently reported (>2 subjects) TEAE, occurring in 13 of 19 subjects (68.4%) and 21 of 30 subjects (70%) for Study #1 and Study #2, respectively. No concerning laboratory findings and no clinically significant findings on vital signs and electrocardiograms were attributed to IMB-115 in study participants.
“Previously completed studies of IMB-115 demonstrated favorable pharmacokinetic properties for an insomnia treatment, including fast absorption, rapid renal elimination and dose-proportional exposure within therapeutic doses. In addition, renal elimination represents the major clearance pathway of IMB-115, lowering the possibility of potential drug-drug-interaction when co-administrated with other drugs. Most importantly, at therapeutic doses IMB-115 showed drug liking responses that were comparable to placebo,” said Mingyan Zhou, PhD, director, Clinical Pharmacology, Imbrium Therapeutics, and study author. “The results from all completed studies provide important new insight into the safety and efficacy of IMB-115 and fully validate the need for the continued evaluation of NOP receptors as a novel target for the treatment of sleep disorders.”
Along with the Phase 1b abstract, Imbrium is presenting three additional abstracts at SLEEP 2020, which explore the potential utility of IMB-115 in targeting NOP receptors as a novel treatment approach for sleep disorders:
- Abstract #0001: “Activation of Nociceptin/Orphanin-FQ Peptide (NOP) Receptors Produces an Increase in Non-REM Sleep in Rats and Constitutes a Novel and Attractive Target for the Treatment of Insomnia”
Oral presentation (Session O-16) Sunday, August 30, 4:00 p.m. – 4:45 p.m. CDT
Poster available during virtual poster hall, August 28-30
- Abstract #0198: “Psychomotor/Cognitive Effects, Pharmacokinetics and Safety of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors, Administered in Combination with Alcohol in Healthy Subjects”
Poster available during virtual poster hall, August 28-30
- Abstract #0500: “Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors”
Poster available during virtual poster hall, August 28-30
Imbrium is further evaluating the possible utility of IMB-115 in the treatment of insomnia associated with alcohol cessation (IAAC), as well as other psychiatric and neurological disorders. In October 2019, Imbrium announced the first dose was administered in a Phase 2 clinical study (OAG2002) evaluating IMB-115 for the treatment of IAAC.
This release discusses an investigational new drug under development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that the investigational drug will successfully complete clinical development or receive regulatory approval.
*Secondary efficacy endpoints included Latency to Persistent Sleep (LPS), Total Sleep Time (TST), Number of Awakenings (NAW), subjective Sleep Latency (sSL), subjective Wakefulness After Sleep Onset (sWASO), subjective Total Sleep Time (sTST), Sleep Quality and Depth of Sleep.
About Imbrium Therapeutics
Imbrium is a clinical stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. We are pursuing treatments for disorders of the central nervous system, non-opioid approaches to the management of pain and oncology chemotherapeutics. A subsidiary of Purdue Pharma L.P., Imbrium strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians and health systems worldwide. We have built a robust and diversified pipeline of investigational drug candidates, and we actively collaborate with industry and academic partners to identify and advance future impactful medicines. For more information, please visit www.imbriumthera.com.
1 Zaveri N. The Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. J Med Chem. 2016; 59(15): 7011–7028.
2 Lambert D. The Nociception/Orphanin FQ Receptor: a Target with Broad Therapeutic Potential. Nat. Rev. Drug Discov. 2008; 7:694–710.
3 American Academy of Sleep Medicine. Insomnia Fact Sheet. Accessed July 2, 2020. Retrieved from https://aasm.org/resources/factsheets/insomnia.pdf.
SOURCE: Imbrium Therapeutics
Post Views: 155
Additional data presentations explore potential utility of targeting NOP receptors in the treatment of insomnia disorders
STAMFORD, CT, USA I August 28, 2020 I Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and subsidiary of Purdue Pharma L.P., today announced results from two Phase 1b studies evaluating the safety, tolerability and efficacy of IMB-115 in patients with insomnia disorder. IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor impairment. The data were shared in an oral presentation (Oral Session O-01) on August 28 and a poster (Abstract ID #502) at the 34th Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2020).
IMB-115 is an internally discovered oral compound with a novel mechanism of action in clinical development for the treatment of sleep disorders, including insomnia. It is designed to bind to and activate the NOP receptor, a protein widely distributed in the central nervous system1 and involved in a wide range of biological functions.2
“Sleep disorders, particularly insomnia, impact millions of people in the U.S. About 10 percent of adults with insomnia experience side effects from treatments that are severe enough to cause daytime consequences;3 these patients often struggle to find relief despite available medications. This reinforces the need to explore new mechanisms in the brain that may contribute to challenges with sleep,” said Paul Medeiros, president, Imbrium Therapeutics. “These data add to the growing body of knowledge around IMB-115 and the NOP receptor pathway and underscore our commitment to advancing medical science to benefit patients.”
IMB-115 was evaluated by nighttime dosing in two separate Phase 1b randomized, double-blind, crossover, placebo-controlled sleep studies using polysomnography (PSG) that evaluated 52 patients with insomnia disorder. In Study #1, 22 patients received either 10 mg of IMB-115 or placebo orally for two consecutive nights. In Study #2, 30 patients received either 0.5, 1, 3 or 6 mg of IMB-115 or placebo orally for two consecutive nights. The primary endpoint for both studies was Sleep Efficiency (SE; or the ratio of the total sleep time divided by the time in bed [8 hours]). Secondary endpoints included Wakefulness After Sleep Onset (WASO; or waking up after falling asleep) and several additional PSG as well as patient diary measures of efficacy.*
Results from both studies demonstrated a dose-dependent, statistically significant and clinically meaningful enhancement in SE (1 mg – 10 mg) and reduction in WASO (0.5 mg – 10 mg), see table below. Additionally, with the exception of Latency to Persistent Sleep (LPS) and subjective Sleep Latency (sSL), the data showed that all other objective and subjective measures of sleep were statistically significantly improved at IMB-115 doses ≥3 mg as compared to placebo. While there was a numeric, dose-dependent trend for improvement in sleep latency with increasing doses of IMB-115, at doses of <3 mg and <10 mg IMB-115 did not achieve statistically significant improvement in sSL and LPS, respectively.
IMB-115
Dose |
N |
Sleep Efficiency (%) |
WASO (min) |
LS Mean
(95% CI) |
P Value |
LS Mean
(95% CI) |
P Value |
| 0.5 mg |
30 |
4.1 (1.7, 6.6) |
0.001 |
-24.3 (-34.5, -14.2) |
<0.001 |
| 1 mg |
30 |
6.7 (4.3, 9.2) |
<0.001 |
-31.8 (-41.9, -21.6) |
<0.001 |
| 3 mg |
29 |
9.7 (7.2, 12.1) |
<0.001 |
-46.4 (-56.6, -36.2) |
<0.001 |
| 6 mg |
30 |
11.0 (8.6, 13.5) |
<0.001 |
-50.8 (-60.9, -40.7) |
<0.001 |
| 10 mg |
19 |
11.8 (7.2, 16.4) |
<0.0001 |
-38.5 (-55.9, -21.0) |
0.0003 |
IMB-115 was well-tolerated across the doses, ranging from 0.5 to 10 mg in both studies. In Study #1, 14 subjects (63.6%) reported treatment-emergent adverse events (TEAEs) of mild severity and 2 subjects (9.1%) reported TEAEs of moderate severity. In Study #2, 21 subjects (70%) reported TEAEs of mild severity and 4 subjects (13%) reported TEAEs of moderate severity. There were no severe TEAEs in either study. There were no AEs leading to study drug withdrawal or discontinuation of treatment with IMB-115. Somnolence (or drowsiness) was the most frequently reported (>2 subjects) TEAE, occurring in 13 of 19 subjects (68.4%) and 21 of 30 subjects (70%) for Study #1 and Study #2, respectively. No concerning laboratory findings and no clinically significant findings on vital signs and electrocardiograms were attributed to IMB-115 in study participants.
“Previously completed studies of IMB-115 demonstrated favorable pharmacokinetic properties for an insomnia treatment, including fast absorption, rapid renal elimination and dose-proportional exposure within therapeutic doses. In addition, renal elimination represents the major clearance pathway of IMB-115, lowering the possibility of potential drug-drug-interaction when co-administrated with other drugs. Most importantly, at therapeutic doses IMB-115 showed drug liking responses that were comparable to placebo,” said Mingyan Zhou, PhD, director, Clinical Pharmacology, Imbrium Therapeutics, and study author. “The results from all completed studies provide important new insight into the safety and efficacy of IMB-115 and fully validate the need for the continued evaluation of NOP receptors as a novel target for the treatment of sleep disorders.”
Along with the Phase 1b abstract, Imbrium is presenting three additional abstracts at SLEEP 2020, which explore the potential utility of IMB-115 in targeting NOP receptors as a novel treatment approach for sleep disorders:
- Abstract #0001: “Activation of Nociceptin/Orphanin-FQ Peptide (NOP) Receptors Produces an Increase in Non-REM Sleep in Rats and Constitutes a Novel and Attractive Target for the Treatment of Insomnia”
Oral presentation (Session O-16) Sunday, August 30, 4:00 p.m. – 4:45 p.m. CDT
Poster available during virtual poster hall, August 28-30
- Abstract #0198: “Psychomotor/Cognitive Effects, Pharmacokinetics and Safety of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors, Administered in Combination with Alcohol in Healthy Subjects”
Poster available during virtual poster hall, August 28-30
- Abstract #0500: “Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors”
Poster available during virtual poster hall, August 28-30
Imbrium is further evaluating the possible utility of IMB-115 in the treatment of insomnia associated with alcohol cessation (IAAC), as well as other psychiatric and neurological disorders. In October 2019, Imbrium announced the first dose was administered in a Phase 2 clinical study (OAG2002) evaluating IMB-115 for the treatment of IAAC.
This release discusses an investigational new drug under development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that the investigational drug will successfully complete clinical development or receive regulatory approval.
*Secondary efficacy endpoints included Latency to Persistent Sleep (LPS), Total Sleep Time (TST), Number of Awakenings (NAW), subjective Sleep Latency (sSL), subjective Wakefulness After Sleep Onset (sWASO), subjective Total Sleep Time (sTST), Sleep Quality and Depth of Sleep.
About Imbrium Therapeutics
Imbrium is a clinical stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. We are pursuing treatments for disorders of the central nervous system, non-opioid approaches to the management of pain and oncology chemotherapeutics. A subsidiary of Purdue Pharma L.P., Imbrium strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians and health systems worldwide. We have built a robust and diversified pipeline of investigational drug candidates, and we actively collaborate with industry and academic partners to identify and advance future impactful medicines. For more information, please visit www.imbriumthera.com.
1 Zaveri N. The Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. J Med Chem. 2016; 59(15): 7011–7028.
2 Lambert D. The Nociception/Orphanin FQ Receptor: a Target with Broad Therapeutic Potential. Nat. Rev. Drug Discov. 2008; 7:694–710.
3 American Academy of Sleep Medicine. Insomnia Fact Sheet. Accessed July 2, 2020. Retrieved from https://aasm.org/resources/factsheets/insomnia.pdf.
SOURCE: Imbrium Therapeutics
Post Views: 155
